Norway-based medical diagnostics company Gentian Diagnostics AS (Euronext Growth Oslo:GENT) said on Friday that its SARS-CoV-2 antibody test is moving to the next development phase.
The project has progressed from the proof-of-concept phase to the project initiation and optimisation phase. Gentian has established an official project plan with an approved budget and a dedicated project team, and the timeline to launch is set for the fourth quarter of 2021.
Gentian's SARS-CoV-2 antibody test is designed to offer the first assay on high-throughput open-access clinical chemistry platforms, supporting COVID-19 vaccination efforts and aiding in community management by the determination of immunisation status.
GC Pharma submits BLA to US FDA for GC5107
AMRI to support Pfizer and BioNTech's COVID-19 Vaccine development in the fight against the pandemic
US FDA's vaccine advisers to consider third possible COVID-19 vaccine for US on 26 February 2021
Jubilant Therapeutics collaborates with Boston Children's Hospital
Shepherd Therapeutics collaborates with Mayo Clinic
Neuvogen appoints new director
China's administrator approves Harbour BioMed's Investigational New Drug application for HBM4003